Continue Reading With Our 7-Day Free Trial
Apellis Pharmaceuticals (NASDAQ:APLS) did not suddenly discover a miracle on Tuesday. What changed was the price investors were willing to pay for the same business. After Biogen agreed to buy the company for $41 a share, valuing the deal at about $5.6 billion, the stock surged toward the offer price. That looked dramatic, but the logic was simple. A market that had treated Apellis like a struggling biotech was forced to reprice it like a strategic asset.
That gap matters because the setup had been hiding in plain sight. The stock had been down sharply, Syfovre sales looked soft, and biotech sentiment had been shaky. Yet Apellis still had two commercial products, a real revenue base, and a pipeline that could matter to a larger buyer.
The business did not become valuable overnight. The public market just stopped ignoring what a strategic acquirer was willing to underwrite. That is what made this jump feel less like a rally and more like a correction.
The Business Looked Worse Than It Really Was
The headline problem was easy to spot. Syfovre sales had slowed, competition from Astellas was real, and investors had lost patience. On the surface, Apellis looked like another biotech that had lost its early shine.
That is the version the market traded for months. It was neat, simple, and mostly incomplete. The company’s own February earnings call painted a messier picture. Syfovre revenue was pressured, but total injections still grew about 17% year over year. Reported sales were also affected by elevated free goods and patient access support, which made the revenue line look weaker than underlying demand.
That distinction is important because markets often punish what they can measure quickly. They do not always pause to ask why the number looks weak. In this case, revenue softness did not automatically mean the franchise had broken.
Apellis described Syfovre as a durable business, with preferred payer status and several tools meant to support growth later on, including a prefilled syringe and functional OCT initiatives. That does not erase the pressure from competitors. It does suggest the market may have treated a difficult phase as a permanent decline.
Biogen’s bid looks, in part, like a buyer deciding those weak optics had gone too far.
Apellis Was More Than A One-Drug Story
A lot of the market conversation centered on Syfovre, which makes sense because it was the larger and louder asset. But the quieter part of the story sat in Empaveli.
That drug generated $102 million in U.S. net product revenue in 2025, and management said its new kidney-disease launch was tracking in line with internal expectations. More notably, Apellis said Empaveli reached more than 5% market penetration after its first full quarter in C3G and primary IC-MPGN. For a rare disease launch in nephrology, that is not the kind of detail a strategic buyer ignores.
This matters because public markets often flatten biotech stories into one question: is the lead asset winning right now or not? Strategic buyers usually ask a broader one: what platform, revenue base, and future indication set are we really buying?
Apellis had two approved drugs on the market, not just one fragile growth narrative. It also had room to expand Empaveli across a small but valuable patient pool, with management pointing to a U.S. addressable population of about 5,000 patients and a long-term goal of treating up to half of that group.
Investors seemed focused on near-term bruises. Biogen appeared more interested in the second engine already starting to turn.
The Real Prize May Have Been Timing, Not Rescue
One of the more interesting parts of the story is that this did not look like a rescue deal. Apellis ended 2025 with $466 million in cash and cash equivalents, and management said it believed the business had the resources to fund operations to profitability.
Operating expenses were being managed with discipline, and the company framed itself as capable of self-funding pipeline progress. That is very different from a biotech racing toward the financing window with no leverage. It means Biogen was not necessarily buying distress. It was buying timing.
That timing likely mattered. Syfovre still had a commercial base. Empaveli was building momentum. The pipeline had programs in focal segmental glomerulosclerosis, delayed graft function, a next-generation geographic atrophy combo strategy, and an FcRn program built around base editing.
Not every program will turn into gold. Big pharma knows that better than anyone. But the combination of existing revenue and future shots on goal can be much more valuable inside a larger portfolio.
Public shareholders often want clean acceleration now. An acquirer can afford to care about what the asset mix looks like in 2027 and beyond. That difference in time horizon helps explain why the stock looked mispriced right up until it did not.
This Was A Violent Repricing, Not A Sudden Rebirth
The most useful way to read the move is also the least romantic. Apellis was around $17 before the announcement. Biogen offered $41 a share, plus contingent value rights tied to Syfovre sales milestones. So the stock jumped toward the new reference point.
That is not the market waking up to a miraculous overnight turnaround. It is the market adjusting to a buyer’s valuation. The business on Monday night and the business on Tuesday morning were essentially the same. What changed was the framework through which investors had to look at it.
That is why the episode feels so revealing. It says less about a company becoming new and more about a market becoming less dismissive. Apellis had already generated $689 million in combined 2025 net sales from Syfovre and Empaveli, based on Biogen’s deal announcement.
The company also had commercial infrastructure, a rare-disease focus, and assets that fit Biogen’s push into immunology, nephrology, and growth areas outside its aging multiple sclerosis franchise. Once a strategic buyer put a price on that mix, the old trading narrative could not survive.
The market had called it damaged. Biogen called it worth billions. Tuesday was what that disagreement looked like when it finally got settled.
Final Thoughts
Apellis now looks less like a failed growth story and more like a case study in how public markets and strategic buyers can value the same biotech very differently. The weakness was real in places. Syfovre faced competition, growth had flattened, and investor sentiment had clearly soured.
But the company also had commercial assets, a second growth driver in Empaveli, and pipeline optionality that a larger buyer could value more confidently than public shareholders did.
From a valuation standpoint, the picture was never simple. Based on the figures provided, Apellis traded at about 5.13x LTM EV/revenue and 5.12x LTM price-to-sales as of March 31, 2026, while profitability-based trailing multiples such as 90.36x LTM EV/EBITDA, 92.90x LTM EV/EBIT, and 233.34x LTM P/E looked stretched and were not especially useful for a business still working through margin and earnings volatility.
That combination suggests the stock was easier to frame on sales and strategic value than on mature profit metrics. In other words, the valuation debate was always going to come down to durability, optionality, and who was willing to pay for both.
Disclaimer: We do not hold any positions in the above stock(s). Read our full disclaimer here.
